Citigroup Inc Omeros Corp Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Omeros Corp stock. As of the latest transaction made, Citigroup Inc holds 41,047 shares of OMER stock, worth $423,194. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,047

Previous 12,871 218.91%

Holding current value

$423,194

Previous $52,000 211.54%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$3.54 - $5.47 $99,743 - $154,122	28,176 Added 218.91%	41,047 $162,000
Q2 2024 Aug 12, 2024	BUY	$3.04 - $4.23 $5,095 - $7,089	1,676 Added 14.97%	12,871 $52,000
Q1 2024 May 10, 2024	BUY	$2.88 - $4.89 $6,981 - $11,853	2,424 Added 27.64%	11,195 $38,000
Q4 2023 Feb 09, 2024	BUY	$1.08 - $3.63 $8,499 - $28,568	7,870 Added 873.47%	8,771 $28,000
Q3 2023 Nov 09, 2023	SELL	$2.81 - $5.69 $51,411 - $104,104	-18,296 Reduced 95.31%	901 $2,000
Q2 2023 Aug 10, 2023	SELL	$4.45 - $7.57 $217,315 - $369,680	-48,835 Reduced 71.78%	19,197 $104,000
Q1 2023 May 11, 2023	BUY	$2.48 - $5.22 $166,846 - $351,185	67,277 Added 8910.86%	68,032 $316,000
Q4 2022 Feb 09, 2023	SELL	$1.75 - $3.96 $5,257 - $11,895	-3,004 Reduced 79.91%	755 $1,000
Q3 2022 Nov 10, 2022	BUY	$3.09 - $7.46 $5,166 - $12,473	1,672 Added 80.11%	3,759 $11,000
Q2 2022 Aug 10, 2022	SELL	$1.92 - $6.28 $21,216 - $69,394	-11,050 Reduced 84.11%	2,087 $6,000
Q1 2022 May 12, 2022	SELL	$5.07 - $7.2 $43,475 - $61,740	-8,575 Reduced 39.49%	13,137 $79,000
Q4 2021 Feb 10, 2022	SELL	$5.67 - $8.54 $25,458 - $38,344	-4,490 Reduced 17.14%	21,712 $140,000
Q3 2021 Nov 10, 2021	BUY	$13.4 - $16.3 $351,106 - $427,092	26,202 New	26,202 $361,000

Others Institutions Holding OMER

# of Institutions

120

Shares Held

25.6M

Call Options Held

228K

Put Options Held

630K

View Full List

About OMEROS CORP

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $647M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

More about OMER

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account